Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.

British journal of cancer - 1 Apr 2022

Nyberg Tommy, Tischkowitz Marc, Antoniou Antonis C

Abstract excerpt

BACKGROUND: BRCA1 and BRCA2 pathogenic variants (PVs) are associated with prostate cancer (PCa) risk, but a wide range of relative risks (RRs) has been reported. METHODS: We systematically searched PubMed, Embase, MEDLINE and Cochrane Library in June 2021 for studies that estimated PCa RRs for male BRCA1/2 carriers, with no time or language restrictions. The literature search identified 27 studies (BRCA1: n = 20,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Heterozygote

Share to Mutation

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34963702
DOI: 10.1038/s41416-021-01675-5
PMCID: PMC8979955

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.PMID 34963702Read ↗

Prostate Cancer Risk by BRCA2 Genomic Regions.Semantic proximity Read ↗

Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention.Semantic proximity Read ↗

Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).Semantic proximity Read ↗

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.Semantic proximity Read ↗

BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.Semantic proximity Read ↗

Integrating Pathogenic Variants, Polygenic Risk Score, and Family History for Prostate Cancer Risk Estimation in Men of African Ancestry.Semantic proximity Read ↗

[Prostate cancer with BRCA2 pathogenic mutation: a clinicopathological analysis].Semantic proximity Read ↗

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.Semantic proximity Read ↗

Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patientsSemantic proximity Read ↗

Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer.Semantic proximity Read ↗

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.Semantic proximity Read ↗

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.